A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency
Open Access
- 1 February 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (7), eaax5701
- https://doi.org/10.1126/sciadv.aax5701
Abstract
Ornithine transcarbamylase (OTC) deficiency is an X-linked urea cycle disorder associated with high mortality. Although a promising treatment for late-onset OTC deficiency, adeno-associated virus (AAV) neonatal gene therapy would only provide short-term therapeutic effects as the non-integrated genome gets lost during hepatocyte proliferation. CRISPR-Cas9-mediated homology-directed repair can correct a G-to-A mutation in 10% of OTC alleles in the livers of newborn OTC spf(ash) mice. However, an editing vector able to correct one mutation would not be applicable for patients carrying different OTC mutations, plus expression would not be fast enough to treat a hyperammonemia crisis. Here, we describe a dual-AAV vector system that accomplishes rapid short-term expression from a non-integrated minigene and long-term expression from the site-specific integration of this minigene without any selective growth advantage for OTC-positive cells in newborns. This CRISPR-Cas9 gene-targeting approach may be applicable to all patients with OTC deficiency, irrespective of mutation and/or clinical state.Funding Information
- National Institute of Child Health and Human Development (P01-HD057247)
- Kettering Family Foundation
This publication has 41 references indexed in Scilit:
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Hepatic Gene Transfer in Neonatal Mice by Adeno-Associated Virus Serotype 8 VectorHuman Gene Therapy, 2012
- AAV8-mediated Hepatic Gene Transfer in Infant Rhesus Monkeys (Macaca mulatta)Molecular Therapy, 2011
- Sustained correction of OTC deficiency in spfash mice using optimized self-complementary AAV2/8 vectorsGene Therapy, 2011
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at ScaleHuman Gene Therapy, 2010
- AAV2/8-mediated Correction of OTC Deficiency Is Robust in Adult but Not Neonatal Spfash MiceMolecular Therapy, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Cross-sectional multicenter study of patients with urea cycle disorders in the United StatesMolecular Genetics and Metabolism, 2008
- Long-Term Correction of Ammonia Metabolism and Prolonged Survival in Ornithine Transcarbamylase-Deficient Mice Following Liver-Directed Treatment with Adeno-associated Viral VectorsMolecular Therapy, 2006